Table Info

Table 1.

Brief description of the treatment for the patients receiving bevacizumab monotherapy

Patient	Age	IHC detection	Date of breast cancer diagnosis	Neoadjuvant therapy	Surgery	Duration of relapse-free interval, months	Date of the detection of metastatic disease	Conventional treatment of metastatic disease	Date of bevacizumab monotherapy administration	Main benefit from bevacizumab, its duration	Survival after the start of bevacizumab, months
Patient 1	54 years	ER^–/PR^–/HER2⁺⁺⁺	August 2019	Doxo + Cyclo, Tax + Trast + Pert	March 2020	19	September 2021	Carbo + Tax + Trast + Pert, Trast + Pert, Lapa + Cape	September 2022	Immediate resolution of coma, 3.5 months	6
Patient 2	68 years	ER⁺/PR^–/HER2⁺⁺⁺	April 2017	*	*	*	April 2017	Doxo + Cyclo, Tax, Carbo + Tax + Trast + Zole, Cape, anastrozole, Tax + Trast + Pert, Trast + Pert, Lapa + Trast, T-DM1	September 2022	Immediate resolution of neurological symptoms, 3.5 months	12+
Patient 3	52 years	ER⁺/PR^–/HER2⁺⁺⁺	December 2015	Cyclo + mitoxantrone + 5-FU	March 2016	27	June 2018	T-DM1, WBRT, Carbo + Tax + Trast + Pert, Trast + Pert, RS, Trast + Pert	December 2022	Partial response, 9+ months	9+
Patient 4	62 years	ER^–/PR^–/HER2⁺⁺⁺	May 2011	None	May 2011	68	January 2017	Tax + Trast, Trast, Carbo + Cape + Trast, Lapa + Cape, T-DM1, Carbo + Tax + Trast + Pert, Trast + Pert, eribulin + Trast, Lapa + Cape, Lapa + Trast	September 2021	Immediate restoration of normal breathing, regression of superficial neck metastases; the duration of the effect could not be estimated because paclitaxel was added starting from the 2nd cycle	5 (death from sepsis)

* Not applicable: initially metastatic disease. IHC: immunohistochemistry; RS: radiosurgery; Doxo: doxorubicin; Cyclo: cyclophosphamide; Tax: taxanes; Trast: trastuzumab; Pert: pertzumab; Carbo: carboplatin; Lapa: labatinib; Cape: capecitabine; Zole: zoledronic acid; 5-FU: 5-fluorouracil; WBRT: whole-brain radiotherapy

Declarations

Acknowledgments

We are cordially thankful to Prof. William R. Miller (University of Edinburgh, UK) and Dr. Vyacheslav A. Chubenko (N.P. Napalkov Cancer Center, Russia) for their invaluable help in improving this manuscript.

Author contributions

AVE: Conceptualization, Investigation, Data curation, Formal analysis. DVN, PSA and TNS: Investigation, Data curation, Formal analysis. ENI: Conceptualization, Writing—original draft, Writing—review & editing, Supervision.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

This study has been approved by the Ethics Committee in the N.N. Petrov Institute of Oncology (approval ID number: 20/25), and the study complies with the Helsinki Declaration.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Informed consent to publication was obtained from relevant participants.

Availability of data and materials

Not applicable.

Funding

This work has been supported by the Russian Science Foundation [21-75-30015]. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Mayer RJ. Two steps forward in the treatment of colorectal cancer. N Engl J Med. 2004;350:2406‒8. [DOI] [PubMed]

Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park). 2005;19:7‒16. [PubMed]

Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, Young D, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol. 2007;14:2367‒76. [DOI] [PubMed]

Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a children’s oncology group study. J Clin Oncol. 2008;26:399‒405. [DOI] [PubMed]

Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: southwest oncology group study S0108. Leuk Lymphoma. 2009;50:728‒35. [DOI] [PubMed] [PMC]

Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3:24‒40. [DOI] [PubMed]

Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. [DOI] [PubMed]

Friedmsan HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733‒40. [DOI] [PubMed]

Chu E, DeVita VT Jr. Physicians’ cancer chemotherapy drug manual. 21st ed. Jones & Bartlett Learning; 2021.

10.

Berghoff AS, Breckwoldt MO, Riedemann L, Karimian-Jazi K, Loew S, Schlieter F, et al. Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases. Neurooncol Adv. 2020;2:vdaa038. [DOI] [PubMed] [PMC]

11.

Bai X, Zhou M. The benefit of bevacizumab therapy in patients with refractory vasogenic edema caused by brain metastasis from lung and colon cancers. Front Oncol. 2022;12:838670. [DOI] [PubMed] [PMC]

12.

Langer CJ. The “lazarus response” in treatment-naïve, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation. J Clin Oncol. 2009;27:1350‒4. [DOI] [PubMed]

13.

Mantica M, Drappatz J, Lieberman F, Hadjipanayis CG, Lunsford LD, Niranjan A. Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme. J Neurooncol. 2023;164:179‒90. [DOI] [PubMed]

14.

Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003;30:117‒24. [DOI] [PubMed]

15.

Zhu M, Costello BA, Yin J, Pettinger AM, Strosberg JR, Erlichman C, et al. Phase II trial of bevacizumab monotherapy in pancreatic neuroendocrine tumors. Pancreas. 2021;50:1435‒9. [DOI] [PubMed]

16.

Oza AM, Dubois F, Hegg R, Hernández CA, Finocchiaro G, Ghiringhelli F, et al. A long-term extension study of bevacizumab in patients with solid tumors. Oncologist. 2021;26:e2254‒64. [DOI] [PubMed] [PMC]

17.

Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, et al. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Ann Oncol. 2018;29:1843–52. Erratum in: Ann Oncol. 2019;30:2013‒4. [DOI] [PubMed] [PMC]

18.

Dempsey N, Sandoval A, Mahtani R. Metastatic HER2-positive breast cancer: is there an optimal sequence of therapy? Curr Treat Options Oncol. 2023;24:1120‒37. [DOI] [PubMed]